NTR-101
AXP000237.1 · Phage therapy
- Platform
- phage preparation
- Originator
- Nterica Bio
- Sponsor
- Nterica Bio
Names
| Name | Type | Source |
|---|---|---|
| NTR-101 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- bacteriophage preparation against cytolysin-positive Enterococcus faecalis
- Replication
- replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06750588 | Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis | Not yet recruiting | Phase 1 | 2025-11-05 | 2026-04 | 12 | Alcohol-Associated Hepatitis |
Recent changes
No changes recorded in its trials yet.
Notes
Phage preparation in a phase 1 trial in acute alcohol-associated hepatitis (NCT06750588), where the target is a cytolysin-producing gut bacterium rather than a wound or lung pathogen. The registration names the target as cytolysin-positive Enterococcus faecalis and screens patients both for E. faecalis and for susceptibility to NTR-101; the cytolysin link to alcohol-associated hepatitis is Duan 2019, Nature 575:505-511.
How to cite
NTR-101 (AXP000237.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000237.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.